Guided Therapeutics (GTHP) Net Income towards Common Stockholders Growth (3y) (2013 - 2025)
Guided Therapeutics (GTHP) Net Income towards Common Stockholders Growth (3y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 60.12% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 29.56% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 31.01% |
| 10 | Guided Therapeutics | 20.78 Mn | 20.72 Mn | 458,000.00 | 13.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.64% |
| Sep 30, 2025 | 9.36% |
| Jun 30, 2025 | 5.27% |
| Mar 31, 2025 | 24.01% |
| Dec 31, 2024 | -11.21% |
| Sep 30, 2024 | -138.51% |
| Jun 30, 2024 | 13.20% |
| Mar 31, 2024 | 8.30% |
| Dec 31, 2023 | -30.48% |
| Sep 30, 2023 | -35.16% |
| Jun 30, 2023 | 38.11% |
| Mar 31, 2023 | -33.08% |
| Dec 31, 2022 | -54.87% |
| Sep 30, 2022 | -103.00% |
| Jun 30, 2022 | 27.60% |
| Mar 31, 2022 | -67.62% |
| Dec 31, 2021 | 43.01% |
| Sep 30, 2021 | 59.31% |
| Jun 30, 2021 | -32.82% |
| Mar 31, 2021 | -36.74% |